Fortress Adds New Rare Disease-Focused Subsidiary

Cyprium joins Fortress’ growing company portfolio, which now includes nine subsidiaries focused on a broad range of disease. Fortress CEO Rosenwald aims to add one to two new companies a quarter under the Fortress umbrella.

microscope

Fortress Biotech Inc. unveiled a new subsidiary March 14, Cyprium Therapeutics, Inc. focused on treatments for the rare pediatric genetic disease Menkes disease and related copper metabolism disorders. Fortress now has nine companies under its umbrella, several of which are developing drugs for rare diseases.

Fortress, which finances each subsidiary company separately and through various means, while retaining an economic stake, has a goal of bringing in one or two new portfolio companies quarterly

Days later, Fortress followed through on its company-building ambitions by

More from Rare Diseases

More from Scrip